$AIM Up 69%! 🚀 🔹 AIM ImmunoTech ripping after spotlighting a new Ebola opportunity for Ampligen 🧬 🔹 Prior BSL-4 preclinical study showed 100% survival with

$AIM Up 69%! 🚀 🔹 AIM ImmunoTech ripping after spotlighting a new Ebola opportunity for Ampligen 🧬 🔹 Prior BSL-4 preclinical study showed 100% survival with early treatment in a lethal Ebola mouse model 🔥 🔹 Company also has Ampligen programs targeting pancreatic cancer, ovarian cancer + antivir…